Literature DB >> 18460106

Interdisciplinary surveillance of intraventricular haemorrhage associated conditions in infants <1000 g.

Michael Obladen1, Boris Metze, Wolfgang Henrich, Ayse Aktas, Christoph Czernik, Annette Schulz-Baldes.   

Abstract

AIM: Intraventricular haemorrhage (IVH) causes some of the most adverse outcomes in infants with birthweight <1000 g. Incomplete antenatal steroids, acidosis, inflammation, postnatal transfer, delayed surfactant administration, hypothermia, hypotension, hypocapnia, persistent ductus arteriosus and pneumothorax are all associated with IVH. We hypothesized that prospective surveillance of these IVH-associated conditions decreases their frequency and thus the frequency of IVH.
METHODS: Cranial ultrasound was performed on days 1, 3, 7, 30 after birth and at discharge, and was assessed according to Papile. The incidence of IVH and IVH-associated conditions was monitored prospectively in all infants <1000 g born in our perinatal centre in 2005/2006, and obstetricians and neonatologists held monthly interdisciplinary review conferences to discuss the preventability of IVH-associated conditions (IVH surveillance). These data were compared to existing prospective data gathered during routine monitoring in 2004.
RESULTS: IVH (all grades) occurred in 29/86 extremely low birthweight (ELBW) infants during routine monitoring and in 12/89 ELBW infants during IVH surveillance (p = 0.007). IVH grades 3-4 dropped from 20% to 3.4% (p = 0.0006). There were significant differences in completeness of antenatal steroids (54% vs. 67%, p = 0.04) and timeliness in initial surfactant substitution (45% vs. 71%, p = 0.01). Most other IVH-associated conditions were reduced during IVH surveillance without reaching significance.
CONCLUSIONS: IVH is not always an inevitable disaster. Obstetricians and neonatologists can reduce its incidence by joint prospective surveillance of IVH-associated conditions.

Entities:  

Mesh:

Year:  2008        PMID: 18460106     DOI: 10.1111/j.1651-2227.2008.00812.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  7 in total

1.  Prevention at the beginning of life: cerebral hemorrhage in very preterm infants.

Authors:  Harald Ehrhardt; Klaus-Peter Zimmer
Journal:  Dtsch Arztebl Int       Date:  2013-07       Impact factor: 5.594

2.  Prospective risk factor monitoring reduces intracranial hemorrhage rates in preterm infants.

Authors:  Manuel B Schmid; Frank Reister; Benjamin Mayer; Reinhard J Hopfner; Hans Fuchs; Helmut D Hummler
Journal:  Dtsch Arztebl Int       Date:  2013-07-22       Impact factor: 5.594

3.  Risk-adjusted intraventricular hemorrhage rates in very premature infants: towards quality assurance between neonatal units.

Authors:  Christoph Vogtmann; Rainer Koch; Dieter Gmyrek; Annette Kaiser; Annette Friedrich
Journal:  Dtsch Arztebl Int       Date:  2012-08-06       Impact factor: 5.594

4.  Impact of low-grade intraventricular hemorrhage on long-term neurodevelopmental outcome in preterm infants.

Authors:  K Klebermass-Schrehof; C Czaba; M Olischar; R Fuiko; T Waldhoer; Z Rona; A Pollak; M Weninger
Journal:  Childs Nerv Syst       Date:  2012-08-23       Impact factor: 1.475

5.  Head Position Change Is Not Associated with Acute Changes in Bilateral Cerebral Oxygenation in Stable Preterm Infants during the First 3 Days of Life.

Authors:  Steve Ming-Che Liao; Rakesh Rao; Amit M Mathur
Journal:  Am J Perinatol       Date:  2014-10-05       Impact factor: 1.862

6.  Head midline position for preventing the occurrence or extension of germinal matrix-intraventricular haemorrhage in preterm infants.

Authors:  Olga Romantsik; Maria Grazia Calevo; Matteo Bruschettini
Journal:  Cochrane Database Syst Rev       Date:  2020-07-07

Review 7.  A Systematic Review and Meta-analysis of the Timing of Early Intraventricular Hemorrhage in Preterm Neonates: Clinical and Research Implications.

Authors:  Sameer Yaseen Al-Abdi; Maryam Ali Al-Aamri
Journal:  J Clin Neonatol       Date:  2014-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.